TGen’s mission is to contribute to and accelerate the research of complex diseases to not only add significantly to what is known about the genetics of each disease, but to also apply that knowledge immediately to help those patients sitting in front of us today and inform clinical decisions for the patients we see tomorrow. TGen tackles human disease utilizing all available technologies to more accurately diagnosis patients and identify the “Achilles’ heel” of each disease such that new, more efficacious and less costly treatments can be developed faster.
About the Ben & Catherine Ivy Foundation
The Ben & Catherine Ivy Foundation, based in Scottsdale, Arizona, was formed in 2005, when Ben Ivy lost his battle with glioblastoma multiforme (GBM). Since then, the Foundation has contributed more than $50 million to research in gliomas within the United States and Canada, with the goal of better diagnostics and treatments that offer long-term survival and a high quality of life for patients with brain tumors.
The Ivy Foundation sponsored GBM initiatives at TGen include research to understand why approximately two percent of GBM patients – the outliers – live far beyond the average survival time of 18 months. By precisely analyzing each patient’s genomic profile, TGen researchers hope to discover the genetic differences between those patients who survive only a few months and those who survive longer because their brain cancer develops more slowly. Using these genetic targets, TGen researchers hope to identify those patients most likely to benefit from the current standard of care and those who might best benefit from alternative or new experimental treatments. These novel treatments will be tested in first-in-patient clinical trial studies that will test promising new drugs that might extend the survival of GBM patients and expedite FDA approval and availability of new drugs that could benefit tens of thousands of brain cancer patients in the future.